These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity's attaining more than 5% in any class of a company's securities. Subsequent changes in holdings or intentions must be reported in amended filings. This material is from Nov. 27 through Dec. 3, 2025. Source: VerityData

Original Filings

Ashland (ASH) Standard Investments disclosed a new position in the specialty chemical maker of 2,625,000 shares. Standard Investments purchased 385,000 of those shares from Nov. 18 through Nov. 24 at per share prices ranging from $48.41 to $51.15. Following the latest purchases, Standard Investments owns a 5.7% stake in Ashland's outstanding stock. Shares of Ashland have lost roughly 16.4% of their value in 2025.

Increases in Holdings

Bitdeer Technologies$(BTDR)$ Tether Holdings raised its stake in the blockchain specialist to 32,244,062 shares. Tether Holdings did so through the purchase of 1,887,531 Bitdeer Technologies shares from Nov. 17 through Nov. 21 at per share prices ranging from $9.70 to $10.15. Following the latest purchases, Tether Holdings owns 14.5% of Bitdeer Technologies' outstanding stock. Shares of Bitdeer have lost approximately 44.9% of their value in 2025.

Decreases in Holdings

Dianthus Therapeutics $(DNTH)$ Fairmount Funds Management lowered its stake in the clinical-stage biotechnology company to 2,139,635 shares. Fairmount Funds Management did so through the sale of 1,170,000 Dianthus Therapeutics shares in a block trade on Nov. 21 at a price of $39.50 per share. Following the latest sale, Fairmount Funds Management continues to own 4.9% of Dianthus Therapeutics' outstanding stock, placing Fairmount below the 5% threshold that would require it to report further sales. Shares of Dianthus Therapeutics have gained roughly 89.5% in value since the beginning of this year.

Centessa Pharmaceuticals $(CNTA)$ General Atlantic reduced its stake in the clinical-stage pharmaceutical company to 7,366,818 shares. General Atlantic did so through the sale of 2,315,000 Centessa Pharmaceuticals shares from Nov. 18 through Nov. 26 at per share prices ranging from $28.03 to $29.22. Following the latest sales, General Atlantic continues to own 5% of Centessa Pharmaceuticals' outstanding stock. Shares of Centessa have gained roughly 66.1% in value since the beginning of this year.

Insight Enterprises(NSIT) ValueAct Capital lowered its stake in the enterprise information-technology company to 1,446,739 shares. ValueAct Capital did so through the sale of 220,000 Insight Enterprises shares from Oct. 29 through Dec. 1 at per share prices ranging from $85 to $105.09. Following the latest sales, ValueAct Capital continues to own 4.7% of Insight Enterprises' outstanding stock, placing ValueAct below the 5% threshold that would require it to report further sales. Shares of Insight Enterprises have lost approximately 40.6% of their value since the beginning of this year.

Email: editors@barrons.com

This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.

(END) Dow Jones Newswires

December 05, 2025 18:35 ET (23:35 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.